Education and Training
CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™
The objective of this study is to evaluate the safety and effectiveness of the MobiusHD System in a prospective, randomized, double-blind, sham-controlled multi-center pivotal study.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: MobiusHD
- other: Sham Implantation
Eligibility
Inclusion Criteria:
- Mean 24 hour ambulatory systolic blood pressure ≥145 mmHg and ≤200 mmHg and stable for
at least 8 weeks on a maximally tolerated guideline directed, (JNC8) or their
equivalent when those listed are not available dosing regimen consisting of up to 5
antihypertensive medications, with a minimum required dosing regimen of an "A+C+D"
antihypertensive medication regimen, where "A" is an angiotensin-converting enzyme
Inhibitor or an angiotensin receptor blocker, "C" is a calcium channel blocker, and
"D" is a diuretic.
Exclusion Criteria:
- Inadequacy of the carotid anatomy for treatment with the MobiusHD based on carotid
angiography.
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting